Find Clinical Trial
Phase I, open label, dose-escalation study to evaluate the safety, expansion, persistence and biological activity of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor), administered intravenously in patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL). – CALM study
← Back
| Study Phase |
Phase 1 |
| Therapeutic Area |
Cancers |
| Indication | Blood cancer |
| Sponsor | Institut de Recherches Internationales Servier (I.R.I.S) |
| Active substance/ Medical device |
UCART19, |
| Active Substance Code | S068587 |
| Protocol Code | CL1-68587-002 |
| EudraCT Code | 2016-000296-24 |
| NCT Code | NCT02746952 |
Documents and links
| Lay summary | |
| Results summary | READ MORE  |
| Scientific publication | READ MORE |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
More information
UCART-19 is anti-CD-19 allogenic CAR-T product developed based on exclusive license granted by Cellectis to Servier. UCART-19 uses Cellectis’ technologies, including TALEN® gene-editing technologies |
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
